Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Interventional × mCRPC × Clear all

Phase

Status

Not yet recruiting 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 639 Carcinoma, Non-Small-Cell Lung 436 Prostatic Neoplasms 379 Neoplasms 345 Multiple Myeloma 241 Colorectal Neoplasms 234 Lung Neoplasms 221 Neoplasm Metastasis 206 Melanoma 202 Ovarian Neoplasms 178 Leukemia, Myeloid, Acute 176 Pancreatic Neoplasms 172 Squamous Cell Carcinoma of Head and Neck 148 Recurrence 139 Glioblastoma 137 Lymphoma 133 Carcinoma, Renal Cell 128 Lymphoma, Non-Hodgkin 126 Stomach Neoplasms 118 Brain Neoplasms 117 Triple Negative Breast Neoplasms 115 Leukemia, Lymphocytic, Chronic, B-Cell 112 Head and Neck Neoplasms 112 Precursor Cell Lymphoblastic Leukemia-Lymphoma 108 Lymphoma, Large B-Cell, Diffuse 104 Carcinoma, Hepatocellular 104 Urinary Bladder Neoplasms 97 Sarcoma 96 Uterine Cervical Neoplasms 94 Colonic Neoplasms 88

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡